Stereotaxis Reports 2025 Full Year Financial Results

Core Insights - Stereotaxis reported a revenue growth of over 20% for the year 2025, driven by significant regulatory approvals and advancements in their product pipeline [2][4] - The company achieved regulatory approvals for key products including the GenesisX robot and MAGiC catheters, which are expected to drive future commercial growth [3][4] Financial Performance - Fourth quarter revenue for 2025 was $8.6 million, a 36% increase from $6.3 million in Q4 2024 [4] - Full year revenue for 2025 totaled $32.4 million, representing a 20% increase from $26.9 million in 2024 [4] - System revenue for the full year grew 18% to $10.2 million, while recurring revenue increased by 21% to $22.2 million [4] Gross Margins and Expenses - Gross margin for Q4 2025 was approximately 50%, while the full year gross margin was about 53% [5] - Operating expenses for Q4 2025 were $10.0 million, with adjusted operating expenses at $7.0 million after excluding non-cash charges [5] Losses - The operating loss for Q4 2025 was ($5.6) million, an improvement from ($7.6) million in Q4 2024 [6] - For the full year 2025, the adjusted operating loss was ($9.3) million, compared to ($12.4) million in 2024 [7] Cash Position - As of December 31, 2025, Stereotaxis had cash and cash equivalents of $13.4 million and no debt [8] - The company raised $3.1 million through an at-the-market offering during Q4 2025 [8] Future Outlook - Stereotaxis anticipates double-digit revenue growth for 2026, expecting annual revenue to surpass $40 million [9] - The company aims to achieve four key milestones in 2026 to support future growth [6][9]